Ruby Cai
Gilead Sciences (United States)(US)
Publications by Year
Research Areas
HIV/AIDS drug development and treatment, HIV Research and Treatment, Hepatitis C virus research, Hepatitis B Virus Studies, Monoclonal and Polyclonal Antibodies Research
Most-Cited Works
- → Inhibition of Respiratory Syncytial Virus Fusion by the Small Molecule VP-14637 via Specific Interactions with F Protein(2003)119 cited
- → Small Molecules VP-14637 and JNJ-2408068 Inhibit Respiratory Syncytial Virus Fusion by Similar Mechanisms(2005)99 cited
- → Discovery of a Potent and Orally Bioavailable Cyclophilin Inhibitor Derived from the Sanglifehrin Macrocycle(2018)76 cited
- → Discovery of GS-9256: A novel phosphinic acid derived inhibitor of the hepatitis C virus NS3/4A protease with potent clinical activity(2011)48 cited
- → Discovery of GS-9451: An acid inhibitor of the hepatitis C virus NS3/4A protease(2012)42 cited
- → Design, synthesis, and SAR studies of novel and highly active tri-cyclic HIV integrase inhibitors(2006)40 cited
- → Effect of substitution on novel tricyclic HIV-1 integrase inhibitors(2006)38 cited
- → GS-9822, a Preclinical LEDGIN Candidate, Displays a Block-and-Lock Phenotype in Cell Culture(2021)31 cited
- → Highly Potent HCV NS4B Inhibitors with Activity against Multiple Genotypes(2014)27 cited
- → Tricyclic HIV integrase inhibitors: Potent and orally bioavailable C5-aza analogs(2008)23 cited